Sentences with word «dabrafenib»

Patients who experienced disease progression on dabrafenib alone were able to cross over into the combination treatment arm.

Researchers have identified characteristics associated with improved outcomes when treating BRAF - mutated advanced melanoma with the combination of dabrafenib and trametinib.

Several agents that directly target BRAF have been approved by the Food and Drug Administration for the treatment of melanoma patients who have the mutation, including dabrafenib and vemurafenib.

Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib + trametinib, vemurafenib + cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature.

A study of this combination showed that trametinib / dabrafenib resulted in an objective response rate of 76 % compared with 54 % in patients treated with the BRAF inhibitor alone.

The MEK inhibitor trametinib and the BRAF inhibitor dabrafenib were approved to treat patients with metastatic or unresectable BRAF - mutated melanoma.

These are the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist)-- which work against faults in a gene called BRAF which are commonly found in melanoma — and the immunotherapy drug nivolumab (Opdivo).

In this video we discuss 3 - year results of the COMBI - d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF - mutated melanoma.

(The FDA recently approved combination treatment in BRAF + melanoma, using dabrafenib against BRAF and trametinib against MEK to delay this escape.)

Results from 599 patients receiving combination targeted therapy of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) were:

Studies have shown that melanoma patients who have both BRAF and PTEN mutations may have a poorer response to dabrafenib and vemurafenib therapy.

Now, a new preclinical study from Penn Medicine researchers found that in many cases the root of the resistance may lie in a never - before - seen autophagy mechanism induced by the BRAF inhibitors vermurafenib and dabrafenib.

Patients were randomized to receive twice daily dabrafenib alone or dabrafenib given in combination with once - a-day trametinib.

Initial data shows that both dabrafenib alone and combined dabrafenib / trametinib therapy are well tolerated by patients, resulting in a 50 to 54 percent response rate among the patients advanced BRAF - mutated papillary thyroid cancer participating in the trial.

The newly FDA - approved therapy, Mekinist (trametinib) in combination with Tafinlar (dabrafenib), is one of the biggest advancements in melanoma treatment in the past 30 years.

Around 40 to 50 per cent of melanoma patients have a faulty BRAF gene and they can be treated with the targeted drugs vemurafenib or dabrafenib.

If the melanoma has a certain mutation of BRAF gene, AMG 232 will be combined with both dabrafenib and trametinib.

The purpose of this study is to assess whether the investigational product, AMG 232, can be given safely in combination with two different drugs to patients with metastatic melanoma: trametinib and dabrafenib or trametinib alone, and to know how AMG 232 is processed and excreted in men and women when combined with these drugs.

These are the BRAF - targeted oral drugs, dabrafenib and trametinib.

She also points out that while the combination of dabrafenib and trametenib earned FDA approval against lung cancer with BRAF V600 mutation in the United States, the combination hasn't yet earned such approval in other countries, and these guidelines are meant to guide care not just in the United States, but internationally.

The targeted therapies are vemurafenib (Zelboraf ®), dabrafenib (Tafinlar ®), trametinib (Mekinist ®), and cobimetinib (Cotellic ®).

Two - thirds of the patients are given a combination therapy (dabrafenib and trametinib) prior to surgery.

«These new data, demonstrating the impact of nivolumab and of dabrafenib and trametinib on stopping melanoma coming back, show how we might use these drugs earlier in the course of the disease.

A phase III trial published last year showed that dabrafenib combined with trametinib in patients with metastatic disease was superior to dabrafenib alone, in terms of progression - free survival (22 % vs 12 % at 3 years; hazard ratio [HR], 0.71) and overall survival (44 % vs 32 % at 3 years; HR, 0.75).

«What we find is that dabrafenib, even at high doses, does not fully turn off the MAPK pathway, thereby enabling eventual escape from drug,» Spencer says.